Avalon GloboCare Corp.
(ALBT)
Add Watchlist
0.28 USD +0.01
Closed: 17 May, 3:55 pm
Symbol ALBT
Market Cap 3M
Price 0.28
Open 0.30
52-wk High 2.42
50 Day Avg 0.31
Earnings Announcement 2024-05-20
Website https://www.avalon-globocare.com
Name Avalon GloboCare Corp.
Shares Outstanding 11,104,500
Change % -3.2975%
Low 0.28
52-wk Low 0.24
200 Day Avg 0.58
Last Dividend 0.00
Exchange NASDAQ
Volume 25,965
Previous Close 0.29
High 0.31
EPS -1.59
PE -0.18
Avg Volume 189,761
CUSIP 05344R203
Avalon GloboCare Corp. Outlook
Description Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Currency USD
ISIN US05344R2031
Industry Real Estate - Services
Changes -0.01
CUSIP 05344R203
Range 0.24 - 2.42
Beta 0.29
CIK 0001630212

Avalon GloboCare Corp. News

23-Apr-2024 8:49 AM

Avalon GloboCare launches KetoAir breathalyzer in the US

Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.

23-Apr-2024 8:49 AM

Avalon GloboCare launches KetoAir breathalyzer in the US

Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.

22-Apr-2024 9:00 AM

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.

28-Mar-2024 9:34 AM

Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer

Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union.   Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.

28-Mar-2024 9:00 AM

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.

18-Dec-2023 9:49 AM

Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU).  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.

18-Dec-2023 9:00 AM

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU).

18-Oct-2023 9:42 AM

Avalon GloboCare partners with Qi Diagnostics on clinical studies of DKAir breathalyzer for diabetic ketoacidosis

Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA). Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.

04-Oct-2023 10:11 AM

Avalon GloboCare debuts KetoAir app on Apple App Store

Avalon GloboCare Corp (NASDAQ:ALBT) has officially unveiled its KetoAir mobile application on the Apple App Store. Coupled with an AI nutritionist and a nanosensor-based breathalyzer, KetoAir serves as a companion diagnostic and monitoring device for individuals practicing a ketogenic lifestyle The app, designed to facilitate ketogenic dietary management, is now also available for download on the Google Play store.

04-Oct-2023 9:00 AM

Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application

KetoAir™ Mobile Application Launches in Apple App  Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store.

13-Sep-2023 9:51 AM

Avalon GloboCare shares spike on Laboratory Services MSO acquisitions

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned clinical diagnostics and reference lab Laboratory Services MSO (LSM) has made two significant accretive acquisitions: Merlin Medical Supply (MMS) and Leading Edge Innovations.  MMS is a home medical equipment and durable medical equipment company operating in Ventura County, California, which has contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health and Gold Coast.